EUCTR2005-000595-40-IT进行中（未招募）不适用
A Phase II study of oral gimatecan ST 1481 in progressing or recurring patients with advanced epithelial ovarian, fallopian or peritoneal cancer, previously treated with platinum and taxanes
SIGMA-TA0 个研究点目标入组 56 人开始时间: 2006年1月3日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 56
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
A Phase II study of oral gimatecan (ST 1481) in progressing or recurring patients with advanced epithelial ovarian, fallopian or peritoneal cancer, previously treated with platinum and taxanesEUCTR2005-000595-40-DESigma Tau Industrie Farmaceutiche Riunite S.p.A.56
进行中（未招募）
不适用
A Phase II study of oral gimatecan (ST 1481) as salvage treatment in patients with advanced or metastatic soft tissue sarcoma relapsing after anthracycline/ifosfamide-based chemotherapy regimeEUCTR2005-001951-39-DESigma Tau Industrie Farmaceutiche Riunite S.p.A.84
进行中（未招募）
不适用
A Phase II study of gimatecan (ST1481) as salvage treatment in patients with advanced or metastatic soft tissue sarcoma relapsing after anthracycline / ifosfamide - based chemotherapy regimeEUCTR2005-001951-39-ITSIGMA-TA
进行中（未招募）
不适用
Phase II study of gimatecan (ST 1481) as salvage treatment in patients with advanced breast cancer after anthracycline /taxanes-based chemotherapy regimeadvanced breast cancerLevel: LLTClassification code 10006285EUCTR2004-005106-79-ESSigma Tau industrie Farmaceutiche Riunite Spa43
已完成
1 期
Phase I study of S 78454 given with a fixed dose infusion of pegylated liposomal doxorubicin in the treatment of primary epithelial ovarian, fallopian tube or primary peritoneal carcinomaPrimary epithelial ovarian, fallopian tube or primary peritoneal carcinomaOther and unspecified female genital organsCancerISRCTN68849558Pharmacyclics LLC (USA)70